Brintuxmabvedodinavd vs. Nivolumabavd: A Better Option for Locally Advanced Rectal Cancer Patients

A thousand patients with stage three or four Hodgkin's lymphoma are randomized to either Brintuxmabvedodinavd which was considered the standard regimen now based off echelon. They're looking at a progression-free survival here as their main endpoint and the nivolumab had a better one-year event- free survival event-free survival. So another option for patients which is great, which means it's going to take more time in these locally advanced rectal cancer patients to talk about their treatment options because now there's another good option to talk about.